COVID-19: Vaccine method questioned: J & J AstraZeneca clinical trial discontinued
-Common items for the two main candidates-
J & J and AstraZeneca vaccines are based on adenovirus
Tests with adenovirus vectors have been successful, but not all
Important common points for vaccines:
The two COVID-19 vaccines discontinued clinical trials due to possible side effects.
In fact, there is one important thing in common.
Both are based on adenovirus.
Johnson & Johnson: (J & J)
Late October 12, the subject announced that the trial was suspended due to unexplained symptoms.
British AstraZeneca:
Vaccine under development with Oxford University.
In a study conducted in the United States, two subjects developed neurological symptoms and were suspended for more than a month.
Moderna and Pfizer Biontech:
Moderna and Pfizer Biontech Coalition lead the vaccine development race in AstraZeneca’s break.
Bloomberg
https://www.bloomberg.co.jp/news/articles/2020-10-19/QIEFJVDWLU6T01
Covid-19 Vaccines: Adenoviruses and Coronavirus Latest Research News and Updates
Experimental shots from J&J, AstraZeneca based on adenoviruses
Past experiments with vectors include successes, failures
Two Covid-19 vaccines stalled by potential side effects have one key feature in common:
Both are based on adenoviruses,
cold germs that researchers have used in experimental therapies for decades with varying results.
Johnson & Johnson said late Monday
it would pause its trial to investigate an illness, which it didn’t specify, in a study participant.
Meanwhile,
AstraZeneca Plc’s U.S. trial of the vaccine
it’s developing with the University of Oxford has been halted by regulators for more than a month after neurological symptoms arose in two volunteers.
With AstraZeneca in a pit stop,
vaccines from Moderna Inc. and the Pfizer Inc.-BioNTech SE partnership have taken the lead in the race to be first out with a shot.
Bloomberg